Investors

Ikena has raised capital from leading biopharma investors in the healthcare industry. We completed a $49 million Series A financing by OrbiMed and Atlas Venture in December 2017. In January 2019, as part of the Bristol-Myers Squibb global strategic collaboration, Ikena received an undisclosed equity investment.

Merck
Merck
Celgene Corporation

Reach out to find out more about how we are discovering and developing cancer therapies.